These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19666215)

  • 41. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics.
    Wunderink L; Nienhuis FJ; Sytema S; Wiersma D
    Schizophr Bull; 2007 May; 33(3):792-6. PubMed ID: 16894026
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term outcome of schizoaffective disorder. Are there any differences with respect to schizophrenia?
    Pinna F; Sanna L; Perra V; Pisu Randaccio R; Diana E; Carpiniello B;
    Riv Psichiatr; 2014; 49(1):41-9. PubMed ID: 24572583
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sociodemographic and clinical factors associated with relapse in schizophrenia.
    Chabungbam G; Avasthi A; Sharan P
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):587-93. PubMed ID: 18081617
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sustained and "sleeper" effects of group metacognitive training for schizophrenia: a randomized clinical trial.
    Moritz S; Veckenstedt R; Andreou C; Bohn F; Hottenrott B; Leighton L; Köther U; Woodward TS; Treszl A; Menon M; Schneider BC; Pfueller U; Roesch-Ely D
    JAMA Psychiatry; 2014 Oct; 71(10):1103-11. PubMed ID: 25103718
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.
    Stahl SM; Malla A; Newcomer JW; Potkin SG; Weiden PJ; Harvey PD; Loebel A; Watsky E; Siu CO; Romano S
    J Clin Psychopharmacol; 2010 Aug; 30(4):425-30. PubMed ID: 20571437
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prediction of symptom remission in schizophrenia during inpatient treatment.
    Jäger M; Riedel M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Buchkremer G; Gastpar M; Bottlender R; Strauss A; Möller HJ
    World J Biol Psychiatry; 2009; 10(4 Pt 2):426-34. PubMed ID: 17853260
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence of remission and recovery in schizophrenia in the Czech Republic.
    Prikryl R; Kholova M; Kucerova HP; Ceskova E
    Compr Psychiatry; 2013 Oct; 54(7):1111-6. PubMed ID: 23810077
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findings.
    Opler MG; Yang LH; Caleo S; Alberti P
    BMC Psychiatry; 2007 Jul; 7():35. PubMed ID: 17650312
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia.
    Rocca P; Montemagni C; Castagna F; Giugiario M; Scalese M; Bogetto F
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):373-9. PubMed ID: 19211031
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Achieving symptomatic remission in out-patients with schizophrenia--a naturalistic study with quetiapine.
    Wobrock T; Köhler J; Klein P; Falkai P
    Acta Psychiatr Scand; 2009 Aug; 120(2):120-8. PubMed ID: 19392812
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance.
    Brissos S; Dias VV; Balanzá-Martinez V; Carita AI; Figueira ML
    Schizophr Res; 2011 Jul; 129(2-3):133-6. PubMed ID: 21514793
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Symptomatic remission and neurocognitive functioning in patients with schizophrenia.
    Hofer A; Bodner T; Kaufmann A; Kemmler G; Mattarei U; Pfaffenberger NM; Rettenbacher MA; Trebo E; Yalcin N; Fleischhacker WW
    Psychol Med; 2011 Oct; 41(10):2131-9. PubMed ID: 21426601
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder.
    Schennach-Wolff R; Meyer S; Seemüller F; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ; Riedel M
    J Psychiatr Res; 2011 Dec; 45(12):1639-47. PubMed ID: 21862035
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data.
    Rabinowitz J; Levine SZ; Garibaldi G; Bugarski-Kirola D; Berardo CG; Kapur S
    Schizophr Res; 2012 May; 137(1-3):147-50. PubMed ID: 22316568
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders.
    Schennach-Wolff R; Jäger M; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Huff W; Heuser I; Maier W; Lemke MR; Rüther E; Buchkremer G; Gastpar M; Möller HJ; Riedel M
    Schizophr Res; 2009 Sep; 113(2-3):210-7. PubMed ID: 19560901
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Minor neurological and physical anomalies in patients with first-episode psychosis].
    Mhalla A; Boussaïd N; Gassab L; Gaha L; Mechri A
    Encephale; 2013 Jun; 39(3):149-54. PubMed ID: 23095597
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Duration of untreated psychosis (DUP): an useful predictor of outcome in schizophrenia?].
    Fuchs J; Steinert T
    Fortschr Neurol Psychiatr; 2004 Feb; 72(2):79-87. PubMed ID: 14770347
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Remission in schizophrenia: a community-based 6-year follow-up study in Bali.
    Kurihara T; Kato M; Reverger R; Tirta IG
    Psychiatry Clin Neurosci; 2011 Aug; 65(5):476-82. PubMed ID: 21851456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.